Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn/Geneva Pharmaceuticals

Executive Summary

Enter marketing agreement for generic versions of two Upjohn products and are negotiating a second agreement covering additional products, Ciba-Geigy subsidiary Geneva announced March 11. The two products covered by the agreement were not named, but the deal is described as part of Upjohn's strategy to reduce the impact of product patent expirations. Top-selling Upjohn products with patents scheduled to expire in the next few years include: Micronase (glyburide -- April 1992); Ansaid (flurbiprofen -- February 1993); Xanax (alprazolam -- September 1993); and Halcion (triazolam -- September 1993).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel